NeuroVive Pharmaceutical AB Interim Report January - March 2019
STOCKHOLM, May 21, 2019 /PRNewswire/ -- Important events January-March 2019
NeuroVive enrolls first subject in its KL1333 phase Ia/b clinical study.
NeuroVive is supplied with approximately MSEK 99.0 in share issue proceeds.
NeuroVive receives SEK 28.2 Million in a directed new share issue.
NeuroVive enters commercial partnership with Oroboros Instruments on mitochondrial medicine research compounds.
Important events after the reporting period
The Supreme Court had delivered its ruling concerning arbitration between NeuroVive and CicloMulsion AG. NeuroVive appealed to the Supreme Court on certain points. The Supreme Court has rejected the appeal.
The US Food and Drug Administration, FDA, has approved NeuroVive's IND (Investigational New Drug) application, enabling clinical studies in the US with the company's drug candidate NeuroSTAT.
Financial information January-March 2019
Net revenues: KSEK 0 (0)
Other operating income: KSEK 0 (174)
Loss before tax: KSEK -13,822 (-13,053)
Loss per share:* SEK -0,12 (-0,25)
Diluted loss per share:** SEK -0,12 (-0,25)
* Profit/loss for the period divided by average number of shares before dilution at the end of the period.
** Profit/loss for the period divided by average number of shares after dilution at the end of the period.
Please find the complete interim report attached below, or through our website www.neurovive.com.
The information was submitted for publication, through the agency of the contact person set out below, at 08:30 a.m. CEST on 21 May 2019.
For more information, please contact: Catharina Johansson CFO IR & Communications +46(0)46-275-62-21 [email protected]
NeuroVive Pharmaceutical AB (publ) Medicon Village SE-223 81 Lund, Sweden Tel: +46(0)46-275-62-20 (switchboard) [email protected] www.neurovive.com
NeuroVive Pharmaceutical AB is a leader in mitochondrial medicine, with one project in clinical phase I (KL1333) for genetic mitochondrial diseases and one project in preparation for a clinical phase II efficacy study for the prevention of moderate to severe traumatic brain injury (NeuroSTAT®). The R&D portfolio also consists of projects for genetic mitochondrial disorders, NASH and cancer. The company advances drugs for rare diseases through clinical development into the market, with or without partners. For projects for common indications the goal is out-licensing in the preclinical phase. A subset of compounds under NeuroVive's NVP015 program has been licenced to Fortify Therapeutics, a BridgeBio company, for local treatment development of Leber's Hereditary Optic Neuropathy (LHON). NeuroVive is listed on Nasdaq Stockholm, Sweden (ticker: NVP). The share is also traded on the OTCQX Best Market in the US (OTC: NEVPF).
The professional membership group of the American Hospital Association focused on healthcare marketing has enlisted experts from the advertising agency universe and the provider data sector to share insights about the best methods for reaching and...
Team famous for HIV breakthroughs demonstrates both persistent COVID virus and widespread immune activation in long COVID; provides clear targets for treatment
Key points:
SARS-CoV-2 double-stranded RNA indicative of viral replication was found in...
CloudMD Software & Services Inc. (the "Company" or "CloudMD"), an innovative health services company transforming the delivery of care, is pleased to announce that it has received a final order from the Supreme Court of British Columbia approving...
Workers at Watsonville Community Hospital represented by Teamsters Local 853 have voted unanimously to ratify a collective bargaining agreement. The new three-year contract includes significant wage increases, a strong benefits package with Teamsters...
The global anti-inflammatory therapeutics market size is estimated to grow by USD 38.7 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of over 6.3% during the forecast period. Increase in off-label use is...
Pulse Biosciences, Inc. (the "Company" or "Pulse Biosciences"), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablationtm (nsPFAtm) technology, announced today the closing of its rights offering and the final results...